Diffusion Pharmaceuticals. has filed a patent for a method to treat gait dysfunction in patients with neurodegenerative diseases affecting the cholinergic forebrain. The method involves administering neflamapimod to patients with conditions like Parkinson’s disease or Dementia with Lewy Bodies. GlobalData’s report on Diffusion Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Diffusion Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Diffusion Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Diffusion Pharmaceuticals's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of gait dysfunction in neurodegenerative diseases using neflamapimod

Source: United States Patent and Trademark Office (USPTO). Credit: Diffusion Pharmaceuticals Inc

A recently filed patent (Publication Number: US20230405005A1) outlines a method for treating gait dysfunction in individuals suffering from forebrain cholinergic neuron degeneration by administering neflamapimod. This method specifically targets conditions such as Parkinson's disease, Dementia with Lewy Bodies (DLB), and alpha synuclein diseases, where forebrain cholinergic neuron degeneration, particularly in the nucleus basalis of Meynert (NBM), is a key factor.

Moreover, the patent also highlights the use of neflamapimod in treating Parkinson's disease by alleviating symptoms such as bradykinesia, rigidity, resting tremor, postural instability, fall risk, and gait dysfunction. The administration of neflamapimod aims to address both continuous and episodic gait dysfunction in individuals with Parkinson's disease, showcasing the potential of this method in improving the quality of life for patients dealing with these debilitating conditions.

To know more about GlobalData’s detailed insights on Diffusion Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies